Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoFRA:D4S -0.35%79 EV-to-OCF is 36.83 as of Sep. 05, 2026, which is 34% above its 10-year median of 27.50. GuruFocus rates FRA:D4S with a GF Score™ of 79/100 and a GF Value™ of €25.97 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Daiichinkyo Co ranks worse than 84.49% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Daiichinkyo Co's Enterprise Value is €27,148 Mil.
Daiichinkyo Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €737 Mil. Therefore, Daiichinkyo Co's EV-to-OCF for today is 36.83.
The historical rank and industry rank for Daiichinkyo Co's EV-to-OCF or its related term are showing as below:
FRA:D4S'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.89 Med: 27.5 Max: 1822.07
Current: 38.37
During the past 13 years, the highest EV-to-OCF of Daiichinkyo Co was 1822.07. The lowest was 5.89. And the median was 27.50.
FRA:D4S's EV-to-OCF is ranked worse than 84.49% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.355
vs FRA:D4S: 38.37
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Daiichinkyo Co's PE Ratio (TTM) for today is calculated as:
Daiichinkyo Co's share price for today is €15.25.
Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.727.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Daiichinkyo Co EV-to-OCF Related Terms
Daiichinkyo Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's EV-to-OCF falls into.
Daiichinkyo Co's current Enterprise Value is €27,148 Mil.
Daiichinkyo Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €737 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (FRA:D4S) has a EV-to-OCF of 36.83 as of Sep. 05, 2026. This is 34% above median its historical median of 27.50. Over the past decade, Daiichinkyo Co's EV-to-OCF has ranged from 5.89 to 1,822.07. According to the industry distribution chart, Daiichinkyo Co ranks #850 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 84.5%.
Is Daiichinkyo Co's EV-to-OCF too high?
Daiichinkyo Co's current EV-to-OCF of 36.83 is 34% above median its 10-year median of 27.50. Over the past 10 years, this metric has ranged from a low of 5.89 to a high of 1,822.07. The Drug Manufacturers industry median EV-to-OCF is 10.36. Daiichinkyo Co's value of 36.83 is 255.7% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #850 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Daiichinkyo Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #850 out of 1006 companies for EV-to-OCF. This places Daiichinkyo Co in the lower half of its industry. The industry median EV-to-OCF is 10.36. Daiichinkyo Co's value of 36.83 is 255.7% above this benchmark. Historically, Daiichinkyo Co's own EV-to-OCF has ranged from 5.89 to 1,822.07 over the past decade. While the company's 10-year median is 27.50 vs. the industry median of 10.36, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.36, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current EV-to-OCF of 36.83 is 255.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current EV-to-OCF is 36.83, which is 34% above median its own 10-year median of 27.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (FRA:D4S) is currently considered Significantly Undervalued. The stock's GF Value™ is €25.97, compared to a current price of €15.25 — trading 41.3% below its estimated fair value. The current EV-to-OCF is 36.83, which is 34% above median its 10-year median of 27.50 and 255.7% above the Drug Manufacturers industry median of 10.36. Daiichinkyo Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Daiichinkyo Co (FRA:D4S), the current EV-to-OCF is 36.83 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (FRA:D4S) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of €15.25 is trading 41.3% below its estimated GF Value™ of €25.97.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for FRA:D4S:
EV-to-OCF: 36.83 (34% above median its 10-year median of 27.50)
GF Value™: €25.97 vs. price of €15.25 (41.3% below fair value)
Industry Position: 255.7% above the Drug Manufacturers median (#850 of 1006)
No single metric tells the full story. See the FRA:D4S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
79GF Score
Get the complete analysis for FRA:D4S
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D4S has been successfully added to your 
